Protocol Ledger

NCT07288489 · Phase III · RECRUITING

Phase 3 Trial of Reltodecacog Alfa (VMX-C001) vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.

Interventional Phase III clinical trial protocol NCT07288489 sponsored by VarmX in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-08-18 Enrollment: 800 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07288489
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)800 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07288489
Protocol FieldVerified Registry Value
NCT IdentifierNCT07288489
Consolidated Lead SponsorVarmX
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment800 participants (ESTIMATED)
Registered Start Date2026-08-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07288489
Hospital Research SiteLocationSite Profile
Stanford Health Care and Stanford Cancer InstituteStanford, CAOpen Hospital Dossier ->
University of South FloridaTampa, FLOpen Hospital Dossier ->
Massachusetts General HospitalBoston, MAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI